TABLE 27, [Mortality data]. - Early high-dose cryoprecipitate to reduce mortality in adult patients with traumatic haemorrhage: the CRYOSTAT-2 RCT with cost-effectiveness analysis

Outcome	Standard care arm (n = 805)	Intervention arm (n = 799)	Overall (n = 1604)	p-value
Mortality at 6 hours from admission, n/N (%)	68/795 (8.6)	56/784 (7.1)	124/1579 (7.9)
OR (95% CI) for mortality at 6 hours from admission^a	0.82 (0.58 to 1.17)		0.2595
Mortality at 24 hours from admission, n/N (%)	97/794 (12.2)	88/783 (11.2)	185/1577 (11.7)
OR (95% CI) for mortality at 24 hours from admission^a	0.91 (0.63 to 1.31)		0.6064
Death from bleeding at 6 hours from admission, n/N (%)	35/795 (4.4)	32/784 (4.1)	67/1579 (4.2)
OR (95% CI) for death from bleeding at 6 hours from admission^a	0.93 (0.54 to 1.58)		0.7675
Death from bleeding at 24 hours from admission, n/N (%)	39/794 (4.9)	43/783 (5.5)	82/1577 (5.2)
OR (95% CI) for death from bleeding at 24 hours from admission^a	1.13 (0.62 to 2.05)		0.6776
Median (IQR) time to death from bleeding among those who bled, in minutes^b	86 (40–205)	191 (81–445)	132 (59–353)	0.0212

Outcome

Standard care arm (n = 805)

Intervention arm (n = 799)

Overall (n = 1604)

p-value

Mortality at 6 hours from admission, n/N (%)

68/795 (8.6)

56/784 (7.1)

124/1579 (7.9)

OR (95% CI) for mortality at 6 hours from admission^a

0.82 (0.58 to 1.17)

0.2595

Mortality at 24 hours from admission, n/N (%)

97/794 (12.2)

88/783 (11.2)

185/1577 (11.7)

OR (95% CI) for mortality at 24 hours from admission^a

0.91 (0.63 to 1.31)

0.6064

Death from bleeding at 6 hours from admission, n/N (%)

35/795 (4.4)

32/784 (4.1)

67/1579 (4.2)

OR (95% CI) for death from bleeding at 6 hours from admission^a

0.93 (0.54 to 1.58)

0.7675

Death from bleeding at 24 hours from admission, n/N (%)

39/794 (4.9)

43/783 (5.5)

82/1577 (5.2)

OR (95% CI) for death from bleeding at 24 hours from admission^a

1.13 (0.62 to 2.05)

0.6776

Median (IQR) time to death from bleeding among those who bled, in minutes^b

86 (40–205)

191 (81–445)

132 (59–353)

0.0212

From: Appendix 2, Additional tables and figures

Cover of Early high-dose cryoprecipitate to reduce mortality in adult patients with traumatic haemorrhage: the CRYOSTAT-2 RCT with cost-effectiveness analysis

Early high-dose cryoprecipitate to reduce mortality in adult patients with traumatic haemorrhage: the CRYOSTAT-2 RCT with cost-effectiveness analysis.

Health Technology Assessment, No. 28.76.

Curry N, Davenport R, Thomas H, et al.

Southampton (UK): National Institute for Health and Care Research; 2024 Nov.

This work was produced by Curry et al. under the terms of a commissioning contract issued by the Secretary of State for Health and Social Care. This is an Open Access publication distributed under the terms of the Creative Commons Attribution CC BY 4.0 licence, which permits unrestricted use, distribution, reproduction and adaptation in any medium and for any purpose provided that it is properly attributed. See: https://creativecommons.org/licenses/by/4.0/. For attribution the title, original author(s), the publication source – NIHR Journals Library, and the DOI of the publication must be cited.

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.